NCT03252938
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03252938
Title Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (INSIGHT)
Acronym INSIGHT
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Helios Klinikum Bad Saarow Bad Saarow 15526 Germany Details
Kliniken der Stadt Köln gGmbH, Studienzentrum der Lungenklinik, Krankenhaus Merheim Cologne 51109 Germany Details
Universitätsklinikum Essen Essen 45147 Germany Details
Agaplesion Markus Krankenhaus Frankfurter Diakonie Kliniken gGmbH Frankfurt 60431 Germany Details
Krankenhaus Nordwest Frankfurt 60488 Germany Details
Universität Gießen und Marburg GmbH Giessen 35392 Germany Details
Hämatologisch Onkologische Praxis Eppendorf (HOPE) Hamburg 20249 Germany Details
Marienhospital Herne, Klinik der Ruhr Universität Bochum, Klinik für Urologie Herne 44625 Germany Details
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz 55131 Germany Details
Universitätsklinikum Tübingen Tübingen 72076 Germany Details
Universitätsklinikum Ulm, Early Clinical Trials Unit (ECTU) Ulm 89081 Germany Details
Helios Dr. Horst Schmidt Klinikum Wiesbaden Wiesbaden 65199 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field